Non-acylated ghrelin does not possess the pituitaric and pancreatic endocrine activity of acylated ghrelin in humans

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

The aim of the present study was to clarify whether non-acylated human ghrelin shares some of the endocrine activities of its acylated form in humans.

Why It Was Studied

Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, displays strong GH-releasing activity mediated by the GH secretagogue (GHS)-receptor (GHS-R) type 1a at the hypothalamus-pituitary level.

Ghrelin and synthetic GHS also possess other GH-independent peripheral endocrine and non-endocrine activities via the activation of peripheral GHS-R subtypes.

Who Took Part

The study group was 7 volunteers.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Ghrelin and who got the comparison, which limits bias.

Some volunteers received a placebo instead of Ghrelin, giving a reference point.

What Was Measured

Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, displays strong GH-releasing activity mediated by the GH secretagogue (GHS)-receptor (GHS-R) type 1a at the hypothalamus-pituitary level.

The subject headings attached to it are Acylation, Adrenocorticotropic Hormone, Blood Glucose, Ghrelin, Human Growth Hormone, Hydrocortisone and Insulin.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Ghrelin in 7 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2003 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Ghrelin compound page, all human trials.